NEW YORK (GenomeWeb) – French synthetic DNA manufacturer DNA Script announced today that it has raised €11 million ($13.1 million) in a Series A financing round.
The round was led by Illumina Ventures — which has received a seat on DNA Script's board — and included investments from Merck KGaA's M Ventures, Sofinnova Partners, Kurma Partners, and Idinvest Partners.
DNA Script said that the funding will be used to advance its enzymatic technology and nucleotide chemistry platform in order to manufacture oligonucleotides more quickly and at lower cost than existing approaches.
"Our new process broadly enables new applications for synthetic DNA and RNA in drug discovery and development, industrial and food technologies, and DNA data storage," DNA Script Cofounder and CEO Thomas Ybert said in a statement. "By applying high-quality oligo synthesis, we believe we can dramatically improve de novo nucleic acid synthesis performance compared to current technologies."